EngineeringBacterial Inclusion Bodies for the Sustained and Remote Release of Tumor-Targeted Protein Drugs

JOAQUÍN SERAS FRONDOZO; UGUTZ UNZUETA; ISOLDA CASANOVA,; MARIA VIRTUDES CESPEDES; RITA SALA,; PATRICIA ÁLAMO,; ALEJANDRO SÁNCHEZ-CHARDI; MIREIA PESARRODONA; LAURA SÁNCHEZ-GARCIA; NAROA SERNA; OLIVIA CANO-GARRIDO; JULIETA M. SANCHEZ; HECTOR LOPEZ LAGUNA; RAMÓN MANGUES; ESTHER VÁZQUEZ; ANTONIO VILLAVERDE

Taiwan

Congreso; 14th AsianCongressonBiotechnology (ACB2019); 2019

Asian Federation of Biotechnology

Bacterial inclusion bodies (IBs) are insoluble, amyloidal protein clusters found inrecombinant bacteria 1. Formed by a combination of functional and non-functional versions of the recombinant protein 2, they act as mechanically stable, sub-micron protein materials with recognized potential in biotechnology, materials sciences and biomedicine 3. Upon intratumoral injection, IB materials are stable, showing a biological impact on surrounding tissues through the sustained release of the forming functional protein 4. When build by tumor-targeted self-assembling proteins, IBs contain assembled oligomers 5 that are slowly released from the bulk material under physiological conditions 6,7. Ifsubcutaneously implanted, such IBs slowly and steadily release functionalproteinnanoparticles that specifically reach target cells through the blood stream 8. IBs can be thus engineered to mimic the human secretory granules from the human endocrine system, for uses in precision medicine.